Tag Archives: BIO Investor Forum

BIO Investor Forum to Showcase NSF-funded Companies

150639480

No risk, no reward—that’s the concept driving the startups and entrepreneurs scheduled to present at next week’s 12th Annual BIO Investor Forum as a part of the newly-announced National Science Foundation (NSF) track of presenting companies. Expanding on the success of the Discovery Track Presentations, the 2013 BIO Investor Forum will feature a dedicated track of 10 NSF-funded companies focused on drug discovery, diagnostics and other related technologies. The companies are supported by the NSF Small Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

New CDC Report on Alarming Rates of Antibiotic-Resistant Infections

MRSA

Every year in the United States, 2 million people acquire an antibiotic-resistant infection. Of those, at least 23,000 die as a result. That’s according to an alarming report  released last week by the CDC. Antibiotic resistance is one of the largest threats to global health. The prevalence of antibiotic-resistant infections is not only a serious world-wide public health issue, it also adds considerable costs to the U.S. healthcare system. According to the CDC: Studies have estimated Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

12th Annual BIO Investor Forum Presenting Companies Announced

San Francisco skyline

Looking to lose a few pounds? Don’t want to diet or exercise? You’re not alone: fully one-third of Americans are obese, and many companies are trying to discover the first blockbuster diet drug and make a dent in the obesity epidemic. We’ll hear from one of those companies next month at the 12th Annual BIO Investor Forum, taking place October 8-9th in San Francisco. Cambridge-based Zafgen is hoping to bring to market their first-in-class obesity Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,